Serum AFBP levels are elevated in patients with nonalcoholic fatty liver disease

References

• Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844–50.
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634–42.
   PubMed Web of Science ®Google Scholar
• Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023–8.
   PubMed Web of Science ®Google Scholar
• Saltiel AR. Series introduction: the molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases. J Clin Invest 2000;106:163–4.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005;54:S73–8.
   PubMed Web of Science ®Google Scholar
• Borregaard N, Cowland JB. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 2006;19:211–15.
   PubMed Web of Science ®Google Scholar
• Makowski L, Hotamisligil GS. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005;16:543–8.
   PubMed Web of Science ®Google Scholar
• Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007;115:1537–43.
   PubMed Web of Science ®Google Scholar
• Choi KM, Yannakoulia M, Park MS, Cho GJ, Kim JH, Lee SH, et al. Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study. Am J Clin Nutr 2011;93:19–26.
   PubMed Web of Science ®Google Scholar
• Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007;30:2667–72.
   PubMed Web of Science ®Google Scholar
• Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology (Baltimore, Md) 2009;49:1926–34.
   PubMed Web of Science ®Google Scholar
• Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356–62.
   PubMed Web of Science ®Google Scholar
• Lee DC, Lee JW, Im JA. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism 2007;56:327–31.
   PubMed Web of Science ®Google Scholar
• Seo JA, Kim NH, Park SY, Kim HY, Ryu OH, Lee KW, et al. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) 2008;68:555–60.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53:34–41.
   PubMed Web of Science ®Google Scholar
• van Dam RM, Hu FB. Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2? Clin Chem 2007;53:5–7.
   PubMed Web of Science ®Google Scholar
• Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J endocrinol 2008;158:203–7.
   PubMed Web of Science ®Google Scholar
• Marignani M, Angeletti S. Nonalcoholic fatty liver disease. N Engl J Med 2002;347:768–9; author reply -9.
   PubMed Web of Science ®Google Scholar
• Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52:405–13.
   PubMed Web of Science ®Google Scholar
• Shen WJ, Sridhar K, Bernlohr DA, Kraemer FB. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc Natl Acad Sci USA 1999;96:5528–32.
   PubMed Web of Science ®Google Scholar
• Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999;48:1987–94.
   PubMedGoogle Scholar
• Coe NR, Simpson MA, Bernlohr DA. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 1999;40:967–72.
   PubMed Web of Science ®Google Scholar
• Makowski L, Hotamisligil GS. Fatty acid binding proteins–the evolutionary crossroads of inflammatory and metabolic responses. J Nutr 2004;134:2464s–8s.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nature reviews Drug discovery 2008;7:489–503.
   PubMed Web of Science ®Google Scholar
• Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004;110:1492–8.
   PubMed Web of Science ®Google Scholar
• Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006;29:2457–61.
   PubMed Web of Science ®Google Scholar
• Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, et al. Retinol-binding protein 4 in human obesity. Diabetes 2006;55:2805–10.
   PubMed Web of Science ®Google Scholar
• Shin MJ, Kang SM, Jang Y, Lee JH, Oh J, Chung JH, et al. Serum retinol binding protein 4 levels are associated with serum adiponectin levels in non-diabetic, non-obese subjects with hypercholesterolemia. Clin Chim Acta 2007;378:227–9.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Lopez R, Berk M, Feldstein AE. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2009;43:985–9.
   PubMed Web of Science ®Google Scholar
• Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003;15:539–43.
   PubMed Web of Science ®Google Scholar